MVIS — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• On July 22, 2026, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split (the “Reverse Stock Split”) of shares of common stock, $0.001 par value. Effe…

• The historical share and per share information included herein have been adjusted to reflect the Reverse Stock Split.

• The increase in research and development expense during the three months ended June 30, 2026 compared to the same period in 2025 was primarily due to higher salary and benefits expense of $3.3 million due to increased headcount from acquisitions (see Part I, Item 1, Note 4. Business Combinations), h…

• The increase in research and development expense during the six months ended June 30, 2026 compared to the same period in 2025 was primarily due to higher salary and benefits expense of $7.0 million, higher one-time employee-related restructuring charges of $1.0 million stemming from the Luminar acq…

• The increase in sales, marketing, general and administrative expense during the six months ended June 30, 2026 compared to the same period in 2025 was primarily due to higher professional and purchased services fees of $4.9 million primarily related to acquisitions, higher salary and benefits expens…

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• The increase in research and development expense during the three months ended March 31, 2026 compared to the same period in 2025 was primarily due to higher salary and benefits expense of $3.7 million due to increased headcount from acquisitions (see Part I, Item 1, Note 4. Business Combinations), …

• The decrease in interest expense during the three months ended March 31, 2026 compared to the same period in 2025 primarily relates to $7.3 million of non-cash interest expense representing the discount on the 2025 Purchase Agreement for warrants and shares of common stock (see Part I, Item 1, Note …

• Unrealized gain on derivative liability reflects the revaluation of our derivative liability associated with notes payable as of March 31, 2026. Due to the decrease in the fair value of the derivative liability as of March 31, 2026 driven primarily by the decrease in our stock price, we recognized a…

• Unrealized gain on warrant liability reflects the revaluation of our warrant liability as of March 31, 2026. Due to the decrease in the fair value of the warrant liability as of March 31, 2026 driven primarily by the decrease in our stock price, we recognized an unrealized gain. See Part I, Item 1, …

• As a result of the debt exchange during the three months ended March 31, 2026 and the debt modification during the three months ended March 31, 2025, we recognized losses on the extinguishment of notes payable. See Part I, Item 1, Note 7. Notes Payable and Derivative Liability for additional discuss…

Text added vs the prior filing · source: 10-Q · 2026-08-06

• ●As of June 30, 2026, we had an accumulated deficit of $1.0 billion.

• ●We incurred net losses of $957.3 million from inception through 2025, and a net loss of $62.2 million during the six months ended June 30, 2026.

• The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and commercialize new technologies. In particular, our operations to date have focused primarily on research and development, initially of our Lase…

• We cannot be certain that we will succeed in securing sustained levels of revenue or commercializing our technology or products at scale. In light of these factors, we expect to continue to incur significant losses and negative cash flow through the remainder of 2026 and the foreseeable future. Ther…

• We will require additional capital to fund our operations at the level necessary to implement our business plan. Raising additional capital will dilute the value of current shareholders’ investment in us. Additionally, we may be unable to raise capital at the level we expect, within the timeframe ne…

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• ● We incurred net losses of $957.3 million from inception through 2025, and a net loss of $25.3 million during the three months ended March 31, 2026.

• The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and commercialize new technologies. In particular, our operations to date have focused primarily on research and development, initially of our Lase…

• We cannot be certain that we will succeed in obtaining additional development revenue or commercializing our technology or products at scale. In light of these factors, we expect to continue to incur significant losses and negative cash flow through the remainder of 2026 and the foreseeable future. …

• We will require additional capital to fund our operations at the level necessary to implement our business plan. Raising additional capital will dilute the value of current shareholders’ investment in us. Additionally, we may be unable to raise capital at the level we expect or on terms acceptable t…

• Based on our current operating plan, including expected financing activities, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months. We will, however, require additional capital to fund our operating plan past that time. We will seek t…